# Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Article · Melanie Jane Davies, Louise Færch, Ole Kleist Jeppesen, Arash Pakseresht, Sue D. Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A. Wadden, Ildiko Lingvay

- Archive id: doi:10.1016/s0140-6736(21)00213-0
- Published: 2021-03-01
- Venue: The Lancet
- DOI: https://doi.org/10.1016/s0140-6736(21)00213-0
- PMID: 33667417
- Citations: 1,419
- Source URL: https://doi.org/10.1016/s0140-6736(21)00213-0
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.